Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

In this case study, a woman with frontal fibrosing alopecia and associated hyperpigmentation showed significant improvement in skin pigmentation and itch after 9 months of treatment with mycophenolate mofetil, highlighting its therapeutic potential for lichen planus pigmentosus linked to this condition.

This study suggests that both the central biosynthesis and metabolism of progesterone to 3α,5α‐THP in the ventral tegmental area are crucial for facilitating lordosis in female rats.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

This study indicated that administering letrozole to Swiss albino mice may have anticonvulsant effects against kainic acid-induced seizures by inhibiting testosterone aromatization to 17β-estradiol and increasing anticonvulsant metabolites in the hippocampus.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.

In this study, low-level light therapy using a new helmet-type device significantly increased hair density and thickness in patients with androgenetic alopecia, showing no adverse events or side effects, suggesting it may be a safe and effective treatment option for both sexes.

This review highlights the potential of drug-loaded extracellular vesicles as a promising drug delivery platform but notes that clinical translation faces challenges due to variability in methods and the need for standardization and safety evaluation.

This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This case report from the University of Alabama describes a rare paradoxical effect where divalproex sodium was associated with increased agitation and hostility in a patient with schizoaffective disorder.

This study found that nanostructured lipid carriers enabled effective follicular delivery and accumulation of anti-hair loss drugs like dutasteride in mice, suggesting potential for reduced dosage frequency.

In this study, researchers found that chitosan-coated PLGA nanoparticles improved the iontophoretic transdermal delivery of the positively charged hydrophilic drug donepezil hydrochloride in an ex vivo rat skin model, achieving 2.2 times higher skin accumulation compared to non-coated nanoparticles.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

This paper discusses the complex relationship between polycystic ovary syndrome (PCOS) and hyperprolactinemia, noting a decrease in prolactin levels following bromocriptine treatment, but reports no new clinical findings.

In this study, the researchers optimized a method for culturing melanocyte precursors from hair follicles and found that 1,25-dihydroxyvitamin D3 significantly promotes their differentiation and melanin synthesis.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This study found that letrozole, an aromatase inhibitor, reduced the incidence and severity of PTZ-induced kindling seizures in mice, potentially due to its effects on 17β-estradiol and neurosteroid synthesis.

This study in a transgenic mouse model found that repressing overexpression of ornithine decarboxylase reduced papilloma development, indicating its role in tumor promotion sensitivity.

This case study reported a rare occurrence of lepromatous leprosy with Lucio phenomenon in a 50-year-old Indonesian living in Malaysia, highlighting the necessity for primary care practitioners, even in non-endemic areas, to recognize this serious leprosy reaction to prevent complications and transmission.

This study found that subcutaneous injections of guanethidine or 6-hydroxydopamine induced premature hair growth in mice, suggesting a role for sympathetic nerves in hair growth control.

This research explores innovative methods to enhance drug delivery to the brain, including techniques like focal intra-arterial administration and temporary blood-brain barrier opening, aimed at improving treatment for brain disorders, the authors report.

This study reviewed the potential of Lupeol, a natural triterpenoid, in promoting hair growth and reducing inflammation related to alopecia, revealing promising molecular pathways and favorable pharmacokinetics while suggesting further research to validate these findings.

This report suggests that fluvoxamine use may be associated with hair loss, as observed in a 28-year-old male whose condition improved after stopping the drug.

The researchers reported that their novel formulation of pterostilbene-loaded ethoniosomes with folic acid coating effectively targeted lung cancer cells in vitro and demonstrated promising results in animal models, indicating potential for future targeted chemotherapy applications.

In this case report, purpura was associated with lithium treatment at therapeutic levels, highlighting the importance of monitoring for symptoms of intoxication even when lithium concentrations appear normal.

In this study, the safety profile of the prodrug CAP7.1 was found to be similar to other topoisomerase inhibitors, with myelosuppression as the main dose-limiting toxicity.